CASP8 and cancer: We also found that the CASP8 -652 6N ins/del polymorphism decreased cancer risk in population-based (DD vs. II: OR=0.83, 95% CI=0.75–0.92) and hospital-based groups (DD vs. II: OR=0.61, 95% CI=0.49–0.75).